Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/31436
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVANHERLE, Sam-
dc.contributor.authorHAIDAR, Mansour-
dc.contributor.authorIROBI, Joy-
dc.contributor.authorBOGIE, Jeroen-
dc.contributor.authorHENDRIKS, Jerome-
dc.date.accessioned2020-07-08T07:29:12Z-
dc.date.available2020-07-08T07:29:12Z-
dc.date.issued2020-
dc.date.submitted2020-07-06T17:04:37Z-
dc.identifier.citationAdvanced drug delivery reviews, 159, p. 322-331.-
dc.identifier.issn0169-409X-
dc.identifier.urihttp://hdl.handle.net/1942/31436-
dc.description.abstractIncreasing evidence indicates that lipid metabolism is disturbed in central nervous system (CNS) disorders, such as multiple sclerosis, Alzheimer's, and Parkinson's disease. Extracellular vesicles (EVs), including exosomes and microvesicles, are nanosized particles that play an essential role in intercellular communication and tissue ho-meostasis by transporting diverse biologically active molecules, including a large variety of lipid species. In the last decade, studies defined that changes in the EV lipidome closely correlate with disease-progression and-remission in CNS disorders. In this review, we summarize and discuss these changes in the EV lipidome and elaborate on the impact of different EV-associated lipids on pathological processes in CNS disorders. We conclude that EV-associated lipids are closely associated with neuroinflammation, CNS repair, and pathological protein aggre-gation in CNS disorders, and that modulation of the EV lipidome represents a promising therapeutic strategy to halt disease progression in multiple sclerosis, Alzheimer's, and Parkinson's disease. Moreover, we predict that disease-stage specific EV-associated lipid signatures can be invaluable markers for the diagnosis and early detection of CNS disorders in the future.-
dc.description.sponsorshipThis work was financially supported by the Research Foundation of Flanders (FWO Vlaanderen, (1S15519N, G099618FWO and 12J9119N)) and Interreg V-A EMR program (EURLIPIDS, EMR23). We thank J. van Haarlem for the graphical representations. We would also like to thank M. Loix, E. Grajchen, and T. Dierckx for revising the manuscript.-
dc.language.isoen-
dc.publisherELSEVIER-
dc.rights2020 Elsevier B.V. All rights reserved.-
dc.subject.otherCNS disorders-
dc.subject.otherExtracellular vesicles-
dc.subject.otherLipids-
dc.subject.otherCNS repair-
dc.titleExtracellular vesicle-associated lipids in central nervous system disorders-
dc.typeJournal Contribution-
dc.identifier.epage331-
dc.identifier.spage322-
dc.identifier.volume159-
local.bibliographicCitation.jcatA1-
local.publisher.placeRADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS-
local.type.refereedRefereed-
local.type.specifiedReview-
dc.identifier.doi10.1016/j.addr.2020.04.011-
dc.identifier.isiWOS:000600557400016-
dc.identifier.eissn-
local.provider.typeCrossRef-
local.uhasselt.uhpubyes-
local.uhasselt.internationalno-
item.validationecoom 2022-
item.contributorVANHERLE, Sam-
item.contributorHAIDAR, Mansour-
item.contributorIROBI, Joy-
item.contributorBOGIE, Jeroen-
item.contributorHENDRIKS, Jerome-
item.accessRightsRestricted Access-
item.fullcitationVANHERLE, Sam; HAIDAR, Mansour; IROBI, Joy; BOGIE, Jeroen & HENDRIKS, Jerome (2020) Extracellular vesicle-associated lipids in central nervous system disorders. In: Advanced drug delivery reviews, 159, p. 322-331..-
item.fulltextWith Fulltext-
crisitem.journal.issn0169-409X-
crisitem.journal.eissn1872-8294-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
1-s2.0-S0169409X20300314-main.pdf
  Restricted Access
Published version1.14 MBAdobe PDFView/Open    Request a copy
Show simple item record

WEB OF SCIENCETM
Citations

23
checked on May 2, 2024

Page view(s)

90
checked on Sep 7, 2022

Download(s)

14
checked on Sep 7, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.